Skip to main content

EXEL STOCK WRITE UP


EXEL (EXELISIS INC)

  • P/E: 800
  • GAAP DILUTED YEAR-OVER-YEAR EPS GROWTH LAST QUARTER: $.31
  • SECTOR: HEALTH TECHNOLOGY
  • ASSETS-LIABILITIES: 1.24
  • DIVIDEND: none
Exilixis is a pharmaceutical company specializing in cancer drugs. The company is up already over 60% YTD. It is heavily owned by the major institutions.
In each of the last 4 quarters, EXEL has beat Wall Street expectations, according to Estimize. The last two quarters have been profitable, and the company has set its expectations for profitable quarters in the future. Previously, the company posted consistent losses. Revenue increased approximately 550% on a year-over-year basis, while collaborative revenue doubled. EXEL has partnerships with Roche and GlaxoSmithKline. Cabometyx, a rectal cancer drug, is its largest revenue source in the latest quarter and most recent drug launch for the company. Exelixis announced that their R&D budget decreased due to decreased costs in one of their drug studies, although the company does have several drugs in its pipeline. Administrative costs were also decreased marginally. Exelixis also has four times as much cash and cash equivalents as it does debt, despite posting losses consistently in the past.
The exorbitant P/E of 800 is calculated based on significant losses realized in FY 2016. Should EXEL hold true to its own estimates or exceed them, it would trade at 133 P/E at the current price. This is still a high P/E multiple comparable to the S&P average, but considering that many biotech companies are not profitable, it is a cheap stock in context.
Michael Morrissey, the CEO, has been in place since 7/2010. He has been with Exelixis since 2000 after working in pharmaceuticals since 1986. He is also an inventor on 68 US patents. Exelixis' largest competitors for cabometyx are produced by Pfizer and Novartis. While Pfizer's market share in the space dropped recently, Exilixis' market share rose. Exelixis is partnering with Pfizer and Novartis competitors Bristol Myers Squibb and Genentech to expand the utilization of cabometyx, thereby taking further market share for the drug.
Exelixis has a recently launched drug for which it is leveraging market competition to gain market share. The company has posted profitable quarters of late, has a clean balance sheet, and has more drugs in the pipeline. It has high institutional ownership, but only 6 analysts have submitted forecasts, according to CNN money. The company took a huge stride up in share price 6/21/17, along with the entire biotech space.





Labels:

Comments

Post a Comment

Popular posts from this blog

PXD STOCK WRITE UP

 PXD (PIONEER NATURAL RESOURCES) P/E: N/A GAAP DILUTED Y-O-Y EPS GROWTH LAST QUARTER: $.67 SECTOR: ENERGY MINERALS ASSETS-LIABILITIES: 1.58 DIVIDEND: .04% Pioneer Natural Resources has recently made the jaw-dropping switch from negative EPS to positive with its last quarter. Situated in the largest oil-producing region in the US, the company is utilizing its good fortune to produce profits. The company has a good balance sheet, a wealth of resources, and a business model which has afforded it growth. This last quarter does not mark the first occasion on which Pioneer has posted a profit. In 2014, and 2012, Pioneer posted a positive EPS for the full year. While the 2016 oil and gas revenues have grown from 2015, the 2014 and 2012 levels were higher. The company's revenue from oil and gas is largely based on market prices. In order to mitigate the market volatility, Pioneer has made efforts to reduce their cost of production, according to their earnin...
1 comment
Read more

AAPL STOCK WRITE UP

AAPL (APPLE) P/E: 17.1 GAAP DILUTED Y-O-Y EPS GROWTH LAST QUARTER: $.2 SECTOR: ELECTRONIC TECHNOLOGY ASSETS-LIABILITIES: 1.67 DIVIDEND: .57% Apple is a technology company famous for their cell phones, tablets, and music store. The company has a solid balance sheet, and a history of earnings growth. The company reported 5/2/2017. Both revenues and gross margins increased, as well as the expenditure on R&D. Therefore, the company posted quality EPS growth in the past quarter. The revenues and EPS beat wall street expectations, and revenue missed estimize's consensus expectation. Cash flows, and accounts receivable, however, decreased in the last quarter. Inventory, which some consider to be a red flag for technology stocks, also increased. Tim Cook has been employed by Apple since 1998, and held the title of CEO since 2011. He is also on the board of directors with Nike. According to IDC, Apple's market share in the cell phone bus...
Post a Comment
Read more

CLS STOCK WRITE UP

CLS (CELESTICA) P/E: 15.1 GAAP DILUTED EPS Y-O-Y GROWTH LAST QUARTER: $.14 SECTOR: ELECTRONIC TECHNOLOGY ASSETS-LIABILITIES: 1.78 DIVIDEND: none Celestica, a spinoff from IBM, manufactures electronics and provides supply chain services for a variety of businesses. The company has successfully improved upon its operating margins and revenue during its last fiscal year. Reporting April 20 th before market open, the company will try to beat Wall street expectations of $.28 and its own guidance of $.24-$.3. Celestica provides services for the communications, consumer, server, and storage industries, as well as working in diversified companies. This wide array of services gives Celestica the opportunity to expand on revenue when one of its segments is lagging. Rather than developing new products to boost revenue, Celestica must rely on increasing customer satisfaction by managing supply chains well for its clients. In order to showcase their services,...
Post a Comment
Read more